WHAT IS CLAIMED IS:

1. A compound structurally represented by Formula I

$$R2$$
 $R1$
 $R1$
 $R6$
 $R6$
 $R6$
 $R6$
 $R6$
 $R6$
 $R1$
 $R1$

or a pharmaceutically acceptable salt thereof wherein:

Q, T, X, and D independently represent carbon or nitrogen, provided that no more than two of Q, T, X, and D are nitrogen;

R1, R2, and R3 are independently at each occurrence

- H,
- halogen,
- $-(C_1-C_7)$ alkyl,
- -CN,
- -C(O)R7,
- $-C(O)(C_3-C_5)$ cycloalkyl,
- -C(O)NR7R8,
- -OCF₃,
- -OR7,
- $-NO_2$,
- -NR7R8,
- -NR9SO₂ R7,

-139-

- -NR9C(O)R7,
- -NR9CO₂R7,
- -NR9C(O)NR7R8,
- -SR7,
- $-SO_2R7$,
- -SO₂CF₃,
- -SO₂ NR7R8,
- -S(O)R7,
- -O(CH₂)mNR7R8,
- heteroaryl-R9,
- -phenyl-R9,

provided however that wherein D is nitrogen, then R1 or R2 or R3 are not attached to D, and provided that wherein X is nitrogen, then R1 or R2 or R3 are not attached to X, and provided that wherein T is nitrogen, then R1 or R2 or R.3 are not attached to T, and provided that wherein Q is nitrogen, then R1 or R2 or R3 are not attached to Q;

and further provided that when D and X are carbon, then R1 and R2 can combine

to form a 5 or 6 membered ring with D and X, , wherein the ring so formed may optionally include one double bond in the case of a five membered ring or two double bonds in the case of a six membered ring, and wherein one to three ring atoms may optionally be heteroatoms independently selected from \mathbb{N} , O, or S;

wherein m is 1, 2, 3 or 4;

R4 and R5 are independently at each occurrence

- -H,
- -OH,
- halogen,

-140-

- -CF₂H,
- -CF_{3,}
- $-(C_1-C_3)$ alkyl,
- $O-(C_1-C_3)$ alkyl,

R6 is independently at each occurrence

- -H,
- halogen,
- -CF3,
- $-(C_1-C_3)$ alkyl,
- -NH₂,
- -NR7R8,
- -OH,
- -OR7;

R7 and R8 are independently at each occurrence

- H,
- (C_1-C_6) alkyl,

Wherein R7 and R8 can combine with the atom to which they are attached to form a 3 to 7 membered ring;

R9 is independently at each occurrence

- H,
- (C_1-C_3) alkyl.
- 2. A compound structurally represented by Formula II

-141-

$$R3'$$
 $R2'$
 X'
 $R1'$
 $R1'$
 $R1'$
 $R6'$
 $R6'$

or a pharmaceutically acceptable salt thereof wherein:

Q', T', X', and D' independently represent carbon or nitrogen, provided that no more than two of Q', T', X', and D' are nitrogen;

R1' is

- halogen,
- $-(C_1-C_7)$ alkyl,
- -CN,
- -C(O)R7',
- -C(O)(C₃-C₅)cycloalkyl,
- -C(O)NR7'R8',
- -OCF₃,
- -OR7',
- $-NO_2$,
- -NR7'R8',
- -NR9'SO₂ R7',
- -NR9'C(O)R7',
- -NR9'CO₂R7',
- -NR9'C(O)NR7'R8',
- -SR7',
- -SO₂R7',

-142-

```
-SO<sub>2</sub>CF<sub>3</sub>,
         -SO<sub>2</sub> NR7'R8',
         -S(O)R7',
         -O(CH<sub>2</sub>)mNR7'R8',
         - heteroaryl-R9',
R2' and R3' are independently at each occurrence
         -H,
         - halogen,
         -(C_1-C_7) alkyl,
         -CN,
         -C(O)R7',
         -C(O)(C_3-C_5)cycloalkyl,
         -C(O)NR7'R8',
         -OCF<sub>3</sub>,
         -OR7',
         -NO_2,
         -NR7'R8',
         -NR9'SO<sub>2</sub> R7',
         -NR9'C(O)R7',
         -NR9'CO<sub>2</sub>R7',
         -NR9'C(O)NR7'R8',
         -SR7',
         -SO<sub>2</sub>R7',
         -SO<sub>2</sub>CF<sub>3</sub>,
         -SO<sub>2</sub> NR7'R8',
          -S(O)R7',
```

-O(CH₂)mNR7'R8',

- heteroaryl-R9',

provided however that wherein D' is nitrogen, then R1' or R2' or R3' are not attached to D', and provided that wherein X' is nitrogen, then R1' or R2' or R3'

-143-

are not attached to X', and provided that wherein T' is nitrogen, then R1' or R2' or R3' are not attached to T', and provided that wherein Q' is nitrogen, then R1' or R2' or R3' are not attached to Q'; wherein m is 1, 2, 3 or 4;

R4' and R5' are independently at each occurrence

-H,

-OH,

- halogen,

 $-CF_2H$

 $-CF_3$

 $-(C_1-C_3)$ alkyl,

- OR9',

provided that when R4' is -H, then R5' is not -H,

R6' is independently at each occurrence

-H,

- halogen,

 $-CF_3$,

 $-CH_{3}$

 $-(C_1-C_3)$ alkyl,

 $-NH_2$,

-NR7'R8',

-OH,

-OR7';

R7' and R8' are independently at each occurrence;

- H,

- (C₁-C₆) alkyl optionally substituted with up to three halogens,

Wherein R7' and R8' can combine with the atom to which they are attached to form a 3 to 7 membered ring;

R9' is independently at each occurrence

- H,
- (C_1-C_3) alkyl.
- 3. The compound of claim 1, wherein D, X, Q and T are carbon.
- 4. The compound of claim 1, wherein one of D, X, Q or T is nitrogen.
- 5. The compound of claim 1 wherein two of D, X, Q or T are nitrogen.
- 6. The compound of claim 1 wherein X is carbon and R1 is attached to X.
- 7. The compound of claim 6 wherein X is carbon and R1 is attached to X, and R4 is halogen.
- 8. The compound of claim 7 wherein one independent occurrence of R6 is -CH₃ and the second independent occurrence of R6 is H.
- 9. The compound of claim 2 wherein X' is carbon and R1' is attached to X'.
- 10. The compound of claim 9 wherein X' is carbon and R1' is attached to X', and R4' is halogen.
- 11. The compound of claim 10 wherein one independent occurrence of R6' is -CH₃ and the second independent occurrence of R6' is H.
- 12. The compound of claim 1 selected from the group consisting of formulae X1 to X115:

Formula	Structure
X1	F F F
X2	F F N

Х3	CI
X4	
X5	
Х6	
Х7	F O N

X8	F ON N
X9	F N
X10	F N
X11	CI
X12	F F N
X13	CI

X14	F F N
X15	
X16	
X17	
X18	

X19	
X20	
X21	
X22	
X23	H ₂ N ⁻ S
X24	

X25	
X26	
X27	O NH
X28	
X29	

X30	
X31	P O N
X32	
X33	
X34	

X35	
X36	
X37	
X38	
X39	F N N N N N N N N N N N N N N N N N N N

X40	
X41	
X42	
X43	
X44	Br
X45	

X46	
X47	
X48	
X49	
X50	
X51	in/

X52	
X53	F N
X54	
X55	
X56	
X57	

X58	
X59	F O N
X60	F F
X61	F O N
X62	F F O N
X63	F O N

X64	F O N N N N N N N N N N N N N N N N N N
X65	F O N
X66	F N N N N N N N N N N N N N N N N N N N
X67	F O N N N N N N N N N N N N N N N N N N
X68	F O N

X69	F F F
X70	F P *,
X71	F F F
X72	F O N
X73	F F F

X74	F F O N N N N N N N N N N N N N N N N N
X75	
X76	F O N
X77	F O N
X78	

X79	F O N
X80	F O N
X81	
X82	F O N O S O O O O O O O O O O O O O O O O
X83	F O N

r	
X84	S, O
X85	F O N
X86	F O N
X87	F O N
X88	


X89	F O N
X90	
X91	F O N N O = S
X92	F F F

_	
X93	F F F
X94	P F F
X 95	F N N F F
X 96	

X97	F N N
X98	F N N
X99	P O N N N N N N N N N N N N N N N N N N
X100	F O N
X101	F O N

X102	F O N
X103	F O N
X104	O S
X105	O S OH
X106	F O N

X107	F O N
X108	F O N N
X109	F S
X110	
X111	
X112	



or a pharmaceutically acceptable salt or solvate thereof.

- 13. The compound of claim 1, selected from the group consisting of
 - (2-(S)-Pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-(4'-trifluoromethyl-biphenyl-4-yl)-methanone;
 - (2-(S)-Pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-(2'-trifluoromethyl-biphenyl-4-yl)-methanone;
 - (4'-Chloro-biphenyl-4-yl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
 - (2'-Chloro-biphenyl-4-yl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
 - [4-(6-Methyl-pyridin-2-yl)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
 - [4'-(5-Methyl-[1,3,4]oxadiazol-2-yl)-biphenyl-4-yl]-(2-pyrrolidin-**1**-ylmethyl-pyrrolidin-**1**-yl)-methanone;

-167-

- (3-Fluoro-biphenyl-4-yl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone trifluoroacetate;
- (3, 2'-Difluoro-biphenyl-4-yl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone trifluoroacetate;
- (2'-Fluoro-biphenyl-4-yl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone trifluoroacetate;
- (4'-Fluoro-biphenyl-4-yl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone trifluoroacetate;
- (2S-Pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-(3'-chloro-biphenyl-4-yl)-methanone;
- (2S-Pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-(3'-trifluoromethyl-biphenyl-4-yl)—methanone;
- (4-Pyrimidin-5-yl-phenyl)- (2S-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (2S-Pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-[4-(6-trifluoromethyl-pyridin-3-yl)]-methanone;
- (3-Chloro-4'-methanesulfonyl-biphenyl-4-yl)- (2S-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (4-Pyridin-3-yl-phenyl)-(2S-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (4-Pyridin-2-yl-phenyl)-(2S-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- 4'-(2S-Pyrrolidin-1-vlmethyl-pyrrolidine-1-carbonyl)-biphenyl-4-carbonitrile;
- (4-Pyridin-2-yl-phenyl)-(2S-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (4-Pyridin-4-yl-phenyl)-(2S-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- 4'-(2S-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carbonyl)-biphenyl-4-sulfonic acid dimethylamide;
- 4'-(2S-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carbonyl)-biphenyl-4-sulfonic acid tert-butylamide;
- 4'-(2S-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carbonyl)-biphenyl-4-sulfonic acid amide;
- 4'-(2S-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carbonyl)-biphenyl-4-sulfonic acid tert-butyl-methyl-amide;

- 4'-(2S-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carbonyl)-biphenyl-4-sulfonic acid methylamide;
- 1-{6-[4-(2-(S)-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carbonyl)-phenyl]-pyridin-3-yl}-ethanone;
- 4'-(2-(S)-Pyrrolidin-ylmeth yl-pyrrolidine-1-carbonyl)-biphenyl-4-carboxylic acid methylamide hydrochloride salt;
- 4'(2-(S)-Pyrrolidin-ylmethyl-pyrrolidine-1-carbonyl)-biphenyl-4-carboxylic acid dimethylamide hydrochloride salt;
- 4'-(Methanesulfonyl-biphen yl-4-yl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- [4'-(Pyrrolidine-1-carbonyl)-biphenyl-4-yl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (3-Fluoro-4'-methanesulfon yl-biphenyl-4-yl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- N-[4'-(2-(S)-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carbonyl)-biphenyl-4-yl]-methanesulfonamide;
- N-[4'-(2-(S)-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carbonyl)-biphenyl-3-yl]-methanesulfonamide;
- (3'-Methanesulfonyl-biphenyl-4-yl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- [4-(6-Ethanesulfonyl-pyridin-3-yl)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone dihydrochloride salt;
- [4-(6-Ethanesulfonyl-pyridin-3-yl)-2-fluoro-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone dihydrochloride salt;
- N-{5-[4-(2-(S)-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carbonyl)-phenyl]-pyridin-2-yl}-methanesulfonamide dihydrochloride salt;
- (2-(S)-Pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-(4'-trifluoromethanesulfonyl-biphenyl-4-yl)-methanone hydrochloride salt;
- N-[3-Fluoro-4'-(2-(S)-pyrro1idin-1-ylmethyl-pyrrolidine-1-carbonyl)-biphenyl-4-yl]-methanesulfonamide;
- (4'-Ethanesulfonyl-biphenyl-4-yl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;

- (S)-(4'-Ni tro-biphenyl-4-yl)-(2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (S)-(4'-Armino-biphenyl-4-yl)-(2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (S)-(4'-Methoxy-biphenyl-4-yl)-(2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone:
- (S)-(4'-Bromo-biphenyl-4-yl)-(2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (S)-(2'-Nitro-biphenyl-4-yl)-(2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (S)-(4'-Eth-yl-biphenyl-4-yl)-(2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (S)-Biphernyl-4-yl-(2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (S)-(4'-Propyl-biphenyl-4-yl)-(2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (S)-[4'-(2-**P**iperidin-1-yl-ethoxy)-biphenyl-4-yl]-(2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (S)-(4'-tert-Butyl-biphenyl-4-yl)-(2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (S)-(4'-Hexyl-biphenyl-4-yl)-(2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (S)-(2-Pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-[1,1'; 3',1"]terphenyl-4-ylmethanone;
- 3-Fluoro-4-pyridin-4-yl-phenyl)-(2S-Pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (2-Fluoro-4'-methanesulfonyl-biphenyl-4-yl)- (2S-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- [4-(2-Methoxy-pyrimidin-5-yl)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- [4-(6-Methoxy-pyridin-3-yl)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;

- (4-Benzo[1,3]dioxol-5-yl-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- [4-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (2-Fluoro-4-pyridin-4-yl-phenyl)-(2 (S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- [2-(S)-(2-Methyl-pyrrolidin-1-ylmethyl)-pyrrolidin-1-yl]-(4'-trifluoromethyl-biphenyl-4-yl)-methanone isomer 1;
- [2-(S)-(2-Methyl-pyrrolidin-1-ylmethyl)-pyrrolidin-1-yl]-(4'-trifluoromethyl-biphenyl-4-yl)-methanone isomer 2;
- (2-Fluoro-3-pyridin-4-yl-phenyl)-(2 (S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (4'-Methanesulfonyl-4-trifluoromethyl-biphenyl-3-yl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (5-Pyridin-4-yl-2-trifluoromethyl-phenyl)-(2-(S)-pyrrolidin-1-yl methyl-pyrrolidin-1-yl)-methanone;
- (3,5-Difluoro-4'-methanesulfonyl-biphenyl-4-yl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (2,6-Difluoro-4-pyridin-4-yl-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- [2,6-Difluoro-4-(2-methoxy-pyrimidin-5-yl)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- N-[3'-Fluoro-4'-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidine-1-carbonyl)-biphenyl-4-yl]-methanesulfonamide;
- N-[3'-Fluoro-4'-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidine-1-carbonyl)-biphenyl-4-yl]-N-methyl-methanesulfonamide;
- [2-(S)-(2-(R)-Methyl-pyrrolidin-1-yl]-(4'-trifluoromethyl-biphenyl-4-yl)-methanone;
- (3-Fluoro-3'-trifluoromethyl-biphenyl-4-yl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (3-Fluoro-4'-trifluoromethyl-biphenyl-4-yl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;

- 3'-Fluoro-4'-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidine-1-carbonyl)-biphenyl-3-carbonitrile;
- (3-Fluoro-3'-trifluoromethoxy-biphenyl-4-yl)-(2-(S)-pyrrol idin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (3-Fluoro-4'-**t**rifluoromethoxy-biphenyl-4-yl)-(2-(S)-pyrrol idin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (3-Fluoro-2', 4'-dimethoxy-biphenyl-4-yl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (3-Fluoro-4'-methoxy-biphenyl-4-yl)-(2-(S)-pyrrolidin-1-yl methyl-pyrrolidin-1-yl)-methan one;
- (3-Fluoro-3', 4'-dimethoxy-biphenyl-4-yl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (3,4'-Difluoro-biphenyl-4-yl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (4-Benzo[1,3]dioxol-5-yl-2-fluoro-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- [4-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-2-fluoro-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (3-Fluoro-3'-pyrrolidin-1-yl-biphenyl-4-yl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (3-Fluoro-3'-rmethanesulfonyl-biphenyl-4-yl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (4'-Ethanesulfonyl-3-fluoro-biphenyl-4-yl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (3-Fluoro-4'-methanesulfinyl-biphenyl-4-yl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (2-Fluoro-4-p yrimidin-5-yl-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- [2-Fluoro-4-(2-methoxy-pyrimidin-5-yl)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- [2-Fluoro-4-(6-methoxy-pyridin-3-yl)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;

- [2-Fluoro-4-(1H-indol-5-yl)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (2-Fluoro-4-quinolin-3-yl-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (3-Fluoro-4'-methanesulfonyl-biphenyl-4-yl)-[2-(S)-(2-(R)-methyl-pyrrolidin-1-yl]-methanone;
- (4'-E than esul fonyl-3-fluoro-biphenyl-4-yl)-[2-(S)-(2-(R)-methyl-pyrrolidin-1-yl]-methyl)-pyrrolidin-1-yl]-methanone;
- [2-(2,5-*trans*-Dimethyl-pyrrolidin-1-ylmethyl)-pyrrolidin-1-yl]-(4'-trifluoromethyl-biphenyl-4-yl)-methanone;
- [2-(2,5-cis-Dimethyl-pyrrolidin-1-yl]-(4'-trifluoromethyl-biphenyl-4-yl)-methanone;
- (2-(R)-Pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-(4'-trifluoromethyl-biphenyl-4-yl)-methanone;
- [2-(S)-(2-(R)-Ethyl-pyrrolidin-1-ylmethyl)-pyrrolidin-1-yl]-(4'-trifluoromethyl-biphenyl-4-yl)-methanone;
- $\label{eq:continuous} \begin{tabular}{l} [2-(S)-(2-(S)-Fluoromethyl-pyrrolidin-1-yl]-(4'-trifluoromethyl-biphenyl-4-yl)-methanone; \end{tabular}$
- (4'-methanesulfonyl-biphenyl-4-yl)-[2-(S)-(2-(R)-methyl-pyrrolidin-1-ylmethyl)-pyrrolidin-1-yl]-methanone;
- (4'-Cyclopropanecarbonyl-3-fluoro-biphenyl-4-yl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- Cyclopropyl-{3'-fluoro-4'-[2-(S)-(2-(R)-methyl-pyrrolidin-1-ylmethyl)-pyrrolidine-1-carbonyl]-biphenyl-4-yl}-methanone;
- (3,5-Difluoro-4'-methanesulfonyl-biphenyl-4-yl)-(2-(R)-methyl-1- (2-(S)-pyrrolidinylmethyl)pyrrolidin-1-yl)- methanone;
- (2-Fluoro-4-[2-methoxy-pyrimidin-5-yl]-phenyl)-(2-(R)-methyl-1-(2-(S)-pyrrolidinylmethyl)pyrrolidin-1-yl)-methanone L-tartrate;
- (2-Fluoro-4-[6-methoxy-pyridin-3-yl]-phenyl)-(2-(R)-methyl-1-(2-(S)-pyrrolidinylmethyl)pyrrolidin-1-yl)-methanone;
- (2-Fluoro-4-pyridin-3-yl-phenyl)-(2-(R)-methyl-1-(2-(S)-pyrrolidinylmethyl)pyrrolidin-1-yl)-methanone;

WO 2005/097740

PCT/US2005/010240

-173-

- (3-Fluoro-4'-methylthio-biphenyl-4-yl)-(2-(R)-methyl-1-(2-(S)-pyrrolidinylmethyl)pyrrolidin-1-yl)- methanone;
- (3-Fluoro-4'-methanesulfinyl-biphenyl-4-yl)-(2-(R)-methyl-1-(2-(S)-pyrrolidinylmethyl)pyrrolidin-1-yl)-methanone;
- 3'-Fluoro-4-[(2-(R)-methyl-1- (2-(S)-pyrrolidinylmethyl)pyrrolidine-1-carbonyl]-biphenyl-4-sulfinic acid;
- [4-(6-Eth anesulfonyl-pyridin-3-yl)-2-fluoro-phenyl]-[2-(S)-(2-(R)-methyl-pyrrolidin-1-ylmethyl)-pyrrolidin-1-yl]-methanone dihydrochloride salt;
- (2,6-Difluoro-4-pyridin-3-yl-phenyl)-((S)-2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (2,6-Difluoro-4-pyrimidin-5-yl-phenyl)-((S)-2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;
- (3,5-Difluoro-4'-methanesulfinyl-biphenyl-4-yl)-((S)-2-pyrrolidin-1-yl methyl-pyrrolidin-1-yl)-methanone;
- ([2,6-Difluoro-4-(5-methoxy-pyridin-3-yl)-phenyl]-((S)-2-pyrrolidin-1-yl)-methanone;
- [2-(S)-(2-(R)-Methyl-pyrrolidin-1-ylmethyl]-(4-pyrimidin-2-yl-phenyl)-methanone;
- [4-(6-Methoxy-pyridin-2-yl)-phenyl]-[2-(S)-(2-(R)-Methyl-pyrrolidin-1-yl]-methanone;
- [2-Fluoro-4-(6-fluoro-pyridin-3-yl)-phenyl]-[2-(S)-(2-(R)-Methyl-pyrrolidin-1-yl]-methanone;
- [4-(6-Fluoro-pyridin-3-yl)-phenyl]-[2-(S)-(2-(R)-Methyl-pyrrolidin-1-ylmethyl)-pyrrolidin-1-yl]-methanone; and
- [4-(6-Methyl-pyridazin-3-yl)-phenyl]-[2-(S)-(2-(R)-Methyl-pyrrolidin-1-ylmethyl)-pyrrolidin-1-yl]-methanone.
- 14. A pharmaceutical composition which comprises a compound of any of claims 1-13 and a pharmaceutically acceptable carrier.
- 15. A method of inhibiting histamine H3 receptor in a mammal comprising administering to a mammal in need thereof a histamine H3 receptor inhibiting dose of a compound of formula I, or a salt thereof, as described in claim 1.

-174-

- 16. A method for treatment or prevention of a nervous system disorder which comprises administering to a mammal in need of such treatment or prevention an effective amount of a compound of any of Claims 1-13.
- 17. The method of Claim 15 wherein the antagonist or inverse agonist is a pharmaceutical composition of claim 14
- 18. A method for treatment or prevention of obesity which comprises administering to a mammal in need of such treatment or prevention an effective amount of a compound of any of Claims 1-13.
- 19. The method of Claim 18 wherein the antagonist is a pharmaceutical composition of claim 14.
- 20. A method for treatment or prevention of a disorder or disease in which inhibition of the histamine H3 receptor has a beneficial effect which comprises administering to a mammal in need of such treatment or prevention an effective amount of a compound of any of claims 1-13.
- 21. A compound of formula I, or a salt thereof, as claimed as claimed in any one of claims 1-13, for use in treating a nervous system disorder.
- 22. The use of a compound of formula I, or a salt thereof, as claimed in any one of claims 1-13, for the manufacture of a medicament for treatment of a nervous system disorder.